Welcome to the Oyster Point Pharma Multimedia page.
The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation.
Tyrvaya® (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.
Please click here for full Prescribing Information.
© 2023 Viatris Inc. and/or its affiliates. All rights reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company. Oyster Point®, the Oyster Point logo, Tyrvaya®, and the Tyrvaya logo are trademarks of Oyster Point Pharma, Inc., a Viatris company, in the United States and certain jurisdictions.